KemPharm, Inc., has announced that the US Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz for the short-term (no >14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. KemPharm, Inc.’s corporate headquarters is located in Coralville, IA.
Indications: Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).
Dosage strengths/administration: Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen. Patients should use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Individualized dosing is based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse.
Adverse reactions: The most common adverse reactions (>5%) are nausea, somnolence, vomiting, constipation, pruritus, dizziness, and headache.
KemPharm announces FDA approval of Apadaz (benzhydrocodone and acetaminophen) for short-term management of acute pain. [news release]. Coralville, IA: KemPharm, Inc. February 23, 2018. http://investors.kempharm.com/news-releases/news-release-details/kempharm-announces-fda-approval-apadaztm-benzhydrocodone-and. Accessed March 15, 2018.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23
FDA Approves Drug for Rare Peripheral Nerve Disease, FDA Web site; 2018 Aug 10